Mobia Medical (MOBI) names ex-PROCEPT CEO Reza Zadno as director
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Mobia Medical, Inc. expanded its Board of Directors from six to seven members and appointed Reza Zadno, Ph.D. as a new Class III director. His term extends until Mobia’s 2029 annual meeting of stockholders, or until a successor is elected and qualified or he departs earlier.
Dr. Zadno was also appointed to the Board’s Compensation Committee, which now comprises Casey Tansey (chair), Dana Mead and Dr. Zadno, following Dr. William Harrington’s resignation from the committee. The Board determined that Dr. Zadno qualifies as an independent director under SEC and Nasdaq rules. He brings prior CEO experience at PROCEPT BioRobotics Corporation and Avedro, Inc., as well as multiple medical device and biopharma board roles. He will be compensated under Mobia’s non-employee director compensation program, and Mobia expects to enter into its standard indemnification agreement with him.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Figures
Board size after change: 7 directors
Board size before change: 6 directors
Director term horizon: 2029 annual meeting
+2 more
5 metrics
Board size after change
7 directors
Board size after appointment of Dr. Reza Zadno on July 14, 2026
Board size before change
6 directors
Board size prior to being increased on July 14, 2026
Director term horizon
2029 annual meeting
Expiration of Dr. Zadno’s Class III director term
PROCEPT CEO tenure
February 2020 to September 2025
Period Dr. Zadno served as President and CEO of PROCEPT BioRobotics
Avedro CEO tenure
September 2016 to November 2020
Period Dr. Zadno served as President and CEO of Avedro, Inc.
Key Terms
independent director, Compensation Committee, Emerging growth company, indemnification agreement
4 terms
independent director regulatory
"the Board determined that Dr. Zadno qualifies as an independent director"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Compensation Committee regulatory
"appointed Dr. Zadno to serve as a member of the Compensation Committee"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
indemnification agreement regulatory
"Mobia expects to enter into its standard form of indemnification agreement"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
FAQ
What board change did Mobia Medical (MOBI) report?
Mobia Medical expanded its Board of Directors from six to seven members and appointed Reza Zadno, Ph.D. as a Class III director. His term runs until the 2029 annual meeting of stockholders, or until a successor is elected and qualified or he leaves earlier.
What is Dr. Reza Zadno’s background relevant to Mobia Medical (MOBI)?
Dr. Reza Zadno previously served as President and CEO of PROCEPT BioRobotics Corporation from February 2020 to September 2025 and of Avedro, Inc. from September 2016 to November 2020. He has held multiple medical device and biopharma board roles and holds Ph.D. and M.Sc. degrees in metallurgy.
Is Dr. Reza Zadno considered an independent director at Mobia Medical (MOBI)?
Yes. Mobia’s Board determined that Dr. Zadno qualifies as an independent director and meets the requirements to serve on the Compensation Committee under applicable SEC regulations and Nasdaq listing standards, indicating he has no relationships requiring disclosure that would impair his independence.
How did Mobia Medical’s (MOBI) Compensation Committee change?
Following Dr. Zadno’s appointment, Dr. William Harrington resigned from the Compensation Committee. The committee now consists of Casey Tansey (chair), Dana Mead and Reza Zadno, aligning its membership with independence requirements under SEC and Nasdaq rules for oversight of executive pay.
What compensation and protections will Dr. Zadno receive at Mobia Medical (MOBI)?
Dr. Zadno will receive compensation as a non-employee director under Mobia’s standard director compensation program. Mobia also expects to enter into its standard form of indemnification agreement with him, providing customary protection for actions taken in his role as director.
When does Dr. Reza Zadno’s term as a Mobia Medical (MOBI) director end?
Dr. Zadno was appointed as a Class III director, with his term expiring at Mobia’s 2029 annual meeting of stockholders. He will continue to serve until that meeting, until his successor is duly elected and qualified, or until any earlier death, resignation, or removal.